Content Type: Commentary & Opinion

Op-Ed: The Trump Administration Is Turning Drug Review Into Make-A-Deal

March 6, 2026

Lowering Drug Prices in the US-Look Within, Not Abroad

March 6, 2026

Overlapping Method of Use Patents to Prevent Generic Entry

March 6, 2026

FDA Regulatory Pathways for Expedited Drug Development and Approval

March 6, 2026

The Limits of Physician-Level Interventions for Cost-Related Nonadherence: A Case for Structural Reform

March 6, 2026

Combating Pharmaceutical Patent Thickets in the Trump Administration

March 6, 2026

Drug Versioning and Legal Accountability (Reply)

March 6, 2026

Benefits and Limitations of Direct-To-Consumer Pharmacies in the US

March 6, 2026

The Advisory Committee on Immunization Practices-Legal Roles, Challenges, and Guardrails

March 6, 2026

Advance Market Commitments and Their Role in Public Innovation

March 6, 2026

Trump’s Ongoing Tariff Chaos Will Make Medications Less Affordable and Harder to Find

March 6, 2026

Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew Results

March 6, 2026